Blog

I recently published two Editorials on the use of STING agonists for cancer immunotherapy, you will find them here:

Berger, Lawler – 2018 – Novel non-nucleotidic STING agonists for cancer immunotherapy

Marloye, Lawler, Berger – 2019 – Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy

Check out my new paper with my Harvard collaborator Sean Lawler on STING for cancer immunotherapy, here!

The adaptor protein STING (STimulator of INterferon Genes) has emerged as a critical mediator of the innate immune system and a promising target for cancer immunotherapy. We carefully reviewed the current status of small molecules agonists of STING in cancer treatment, highlighting successes and limitations. Since its discovery, STING activation in cancer has shown tremendous potential in restoring anti-tumor immunity and potentiate other immunotherapies.

Check out our JACS paper on the fate of phenanthriplatin in the core of the Tobacco Mosaic Virus – and efficient and promising anticancer nanomedicine

https://pubs.acs.org/doi/10.1021/jacs.7b12697

New site is up, enjoy!

Please find an introduction to theoretical methods as used in computational chemistry, which I wrote some time ago:

Theoretical Methods and Computational Chemistry

© Dr. Gilles BERGER